Integrating large-scale serum metabolomics and *APOE* ε4 genotype status for the non-invasive detection of Alzheimer's disease in the ADNI cohort

Authors:

Dany Mukesha [1,2,3*], Hüseyin Firat [1], Guillaume Sacco [2,3]

Affiliations:

[1]**Firalis SA**, Huningue, France

[2]**Centre Hospitalier Universitaire de Nice**, Nice, France

[3]**Université Côte d'Azur**, INSERM, CNRS, IPMC, Nice, France

*Corresponding Author:

dany.mukesha@firalis.com;/ danymukesha@gmail.com

All authors contributed equally to this work.

Abstract

INTRODUCTION: Accurate Alzheimer's disease (AD) detection remains challenging and often requires invasive or costly procedures. Blood-based metabolomic signatures offer a promising non-invasive approach. This study aimed to identify a serum metabolite panel and evaluate its performance alone and in combination with *apolipoprotein E* (*APOE*) ε4 genotype status for distinguishing AD from cognitively normal (CN) individuals.

METHODS: Baseline data from 594 participants in the Alzheimer's Disease Neuroimaging Initiative (237 AD, 357 CN) were analyzed. High-resolution serum metabolomics (Biocrates MxP® Quant 500) and *APOE* genotype data were used for LASSO-based feature selection, followed by machine learning model training and evaluation on a held-out test set.

RESULTS: A panel of 151 metabolites distinguished AD from CN with high accuracy (test-set AUC=0.90). Adding *APOE* to the panel further improved model performance (AUC=0.91 versus AUC=0.75 for *APOE* alone; $p<0.001$), achieving strong sensitivity (0.92), specificity (0.84), and negative predictive value (0.94). Key predictive metabolites included bile acids, ether-linked phosphatidylcholines, and acylcarnitines, which are associated with pathways related to lipid metabolism, mitochondrial function, and the gut–liver–brain axis.

CONCLUSION: Integrating serum metabolomics with *APOE* enables accurate, non-invasive AD detection and offers a scalable screening approach with strong potential to rule out AD in primary care.

ClinicalTrials.gov Identifier: NCT00106899 and related ADNI phases.

33 1. Introduction

The global landscape of Alzheimer's disease (AD) diagnostics is currently undergoing a

transformative shift, driven by the increasing clinical precision and expanding diagnostic

accessibility. As of 2024 and 2025, the traditional reliance on invasive lumbar punctures for

cerebrospinal fluid (CSF) analysis and high-cost positron emission tomography (PET) imaging

has been challenged by the emerging high-performance blood-based biomarkers (BBMs) (1–

3). This transition is not merely a change in methodology but a fundamental evolution in how

the disease is defined, staged, and managed in clinical practice. The 2024 National Institute on

Aging-Alzheimer's Association (NIA-AA) revised criteria have established AD as a biological

process, defined by the presence of core biomarkers of amyloid and tau pathology, regardless

of the clinical symptomatic state (4), However, this biological focus has sparked significant

debate within the scientific community. Critics, such as the International Working Group

(IWG) led by Dubois and colleagues in 2024 (5), argue that AD should remain a clinical-

biological construct, requiring both biological evidence of pathology and the presence of

objective cognitive symptoms for a formal diagnosis. This tension underscores a critical need

for biomarkers that do more than just detect protein aggregates. Therefore, there is a demand

for signatures that reflect the systemic physiological state and the metabolic disruptions that

drive the progression from early amyloidosis to active, symptomatic neurodegeneration.

Metabolomics, the study of low-molecular-weight metabolites in biological systems, offers a

uniquely high-resolution window into these complex pathophysiological shifts. Unlike the

genome, which provides a static blueprint of risk, the metabolome is dynamic, reflecting the

ongoing interactions between genetics, environment, lifestyle, and disease state. In the context

of AD, metabolomics has the potential to capture early signatures of mitochondrial

dysfunction, oxidative stress, lipid membrane remodeling, and neurotransmitter imbalance,

processes that often preceded the widespread accumulation of amyloid plaques and tau tangles.

Large-scale epidemiological investigations, including studies using the UK Biobank dataset (n

≈ 274,000), have already demonstrated that blood-based metabolite profiling can predict

incident AD with robust accuracy, particularly when signatures of lipoprotein metabolism,

branched-chain amino acids, and glucose homeostasis are integrated with demographic and

cognitive features (6–8).

Despite these advances, many prior metabolomics studies have been limited by small sample

sizes, a lack of standardized quantification platforms, or a failure to fully integrate metabolic

data with the most potent genetic risk factor for sporadic AD: the *apolipoprotein E* (*APOE*) ε4

allele. The *APOE* ε4 isoform is central to the AD narrative, as it is known to impair lipid

transport, reduce amyloid clearance, and exacerbate neuroinflammatory responses. The current

study seeks to address these gaps by leveraging the Alzheimer's Disease Neuroimaging

Initiative (ADNI) cohort, utilizing the Biocrates MxP® Quant 500 platform for absolute

quantification of serum metabolites, and applying advanced machine learning to identify a

reproducible metabolic signature that distinguishes AD from cognitively normal (CN)

individuals at baseline.

2. Material and methods

Study population and ADNI cohort selection

We analyzed data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), a landmark

multicenter longitudinal study designed to develop and validate clinical, imaging, genetic, and

biochemical biomarkers for the early detection and tracking of AD. The ADNI project, which

began in 2004, has progressed through several phases (ADNI-1, ADNI-GO, ADNI-2, and

ADNI-3), recruiting participants across North America. From an initial pool of 2,418

participants, we carefully selected a sub-cohort of 594 individuals who possessed definitive

baseline diagnoses and complete serum metabolomic data.

The diagnostic classification for this cohort was rigorous. The AD group (n=237) consisted of

patients meeting the 2024 NIA-AA framework criteria for confirmed AD (9,10). These

individuals exhibited objective cognitive impairment, typically characterized by memory

complaints verified by a study partner, abnormal scores on the Wechsler Memory Scale

(logical memory II), and Mini-Mental State Examination (MMSE) scores between 20 and 26.

The cognitively normal (CN) control group (n=357) was defined by MMSE scores between 28

and 30, a Clinical Dementia Rating (CDR) Sum of Boxes (CDR-SB) score of 0, and no

evidence of significant depression or other confounding psychiatric conditions. Exclusion

criteria were strictly applied to ensure the specificity of the metabolic markers; participants

with comorbid neurological disorders (such as Parkinson's disease or stroke), major psychiatric

illness (such as schizophrenia or major depressive disorder), or incomplete metabolomic data

were removed from the analysis. The demographic profile of all the participants included age,

sex, race, and education level are summarized in the Results section.

The study was approved by institutional review boards at all participating sites, and written

informed consent was obtained from all participants prior to the sample collection. Data is

available through the ADNI repository. Further information regarding the study protocol can

be found at *ClinicalTrials.gov* under identifier NCT00106899.

99 Metabolomics profiling and technical specifications

Serum samples were analyzed using the Biocrates MxP® Quant 500 kit, a high-resolution mass

spectrometry platform that allows for the absolute quantification of a broad spectrum of

metabolites (Fig 1). The Quant 500 panel is designed to cover up to 630 metabolites across

several major biochemical families. The platform utilizes a combination of liquid

chromatography-tandem mass spectrometry (LC-MS/MS) and flow injection analysis (FIA).

This dual approach ensures high sensitivity for polar metabolites like amino acids and biogenic

amines, while providing robust quantification for complex lipids.

<u>Fig 1.</u> From serum metabolomics patterns to predictive models for accurate detection of

AD.

The study analyzed metabolomic profiles from 594 participants (AD vs. CN) in the ADNI

cohort, measuring up to 630 serum metabolites. Machine learning was applied to develop

predictive models, with performance evaluated using AUC (area under the curve) to assess

diagnostic accuracy for baseline AD detection. The goal was to derive a highly accurate

metabolic signature capable of distinguishing AD from CN individuals at baseline. The

workflow highlights the potential of systems-level metabolomics combined with predictive

modeling to uncover reproducible biomarkers for AD, addressing the need for non-invasive,

scalable screening tools.

Rsigorous data preprocessing and quality control (QC) pipeline was implemented. Initial steps

involved the exclusion of metabolites with a high prevalence of missing values (>20%). For the

remaining metabolites, missing values were imputed using k-nearest neighbors (k=5), a method

that leverages the local structure of the data to provide accurate estimations. Data

normalization was achieved via probabilistic quotient normalization (PQN), which corrects for

global differences in metabolite concentrations across samples and mitigates batch effects. To

ensure technical reliability, any metabolite measurement with a coefficient of variation (CV)

exceeding 25% in reference QC samples was discarded. After these quality filtering steps, the

final dataset consisted of 623 high-quality metabolites ready for downstream machine learning

analysis.

Feature selection and machine learning pipeline

The analysis aimed to identify the most discriminative metabolic features and build a

predictive model optimized for AD detection. The dataset was split into a training set (70% of

the cohort, n ≈ 416) and an independent test set (30% of the cohort, n ≈ 178). All feature

selection and model tuning were performed exclusively within the training set to prevent

optimistic bias and data leakage.

Feature selection was conducted using the least absolute shrinkage and selection operator

(LASSO) regression. LASSO is a regularized regression method that adds an L1 penalty to the

objective function, effectively shrinking the coefficients of less important variables to zero.

This sparsity-inducing property is particularly valuable for metabolomic datasets where high

dimensionality and multicollinearity are prevalent. The optimal value for the tuning parameter

λ (lambda) was determined using repeated 5-fold cross-validation (Fig S1). Following feature

selection, we trained and compared five distinct machine learning algorithms: LASSO, partial

least squares (PLS), random forest, extreme gradient boosting (XGBoost), and naive bayes.

Models were developed using repeated 5-fold cross-validation (20 repetitions) with

stratification by diagnosis and *APOE* status. Potential confounding variables, including age and

sex, were adjusted for prior to model construction to ensure that the identified metabolic

associations were robustly linked to AD status rather than demographic shifts.

Performance evaluation and statistical framework

Three feature sets were evaluated: (1) metabolomic data alone, (2) *APOE* ε4 carrier status, and

(3) combined metabolomic + *APOE* genotype data. A held-out test set was used for final

evaluation. Primary metric for evaluating model performance was the area under the receiver

operating characteristic curve (AUC-ROC). The ROC curve plots the true positive rate

(sensitivity) against the false positive rate (1-specificity) across various decision thresholds. To

ensure the statistical reliability of the performance estimates, 95% confidence intervals (CIs)

were calculated using 2000 stratified bootstrap replicates. Secondary metrics, reported at the

optimal decision threshold determined by Youden's index, included sensitivity (Recall),

specificity, positive predictive value (PPV), and negative predictive value (NPV). Pairwise

comparisons between AUCs were conducted using the DeLong test (11). To further confirm

that the models were not overfitted to noise, permutation testing was performed (12,13). This

involved shuffling the diagnostic labels 1000 times to build a null distribution of AUC values,

against which the actual model performance was compared to establish a p-value. All statistical

analyses were performed using R version 4.3.0, the *pROC* package(14) for ROC analyses and

the *caret* package(15) for machine learning model development and cross-validation.

3. Results

Demographic and clinical profile

There were no statistically significant differences in age, sex, or race between groups. As

expected, cognitive performance measures, including Mini-Mental State Examination (MMSE)

and Clinical Dementia Rating Scale-Sum of Boxes) CDR-SB scores, demonstrated clear

separation between diagnostic groups. The *APOE* ε4 allele was significantly more prevalent

among participants with AD, consistent with established genetic risk patterns. Detailed

demographic and clinical characteristics are summarized in Table 1.

Table 1. Baseline Characteristics of the Study Cohort

Characteristic	Total (N=594)	AD (n=237)	CN (n=357)	P-value [95% CI]
Demographics				
Age, years, mean (SD)	75.0 (6.6)	75.0 (7.7)	75.0 (5.8)	0.354† [-0.8, 1.5]
Female sex, n (%)	277 (46.6%)	105 (44.3%)	172 (48.2%)	0.569‡ [-4.3, 12.0]
Education, n (%)				<0.001†
< High School	23 (3.9%)	16 (6.8%)	7 (2.0%)	
High School	70 (11.8%)	39 (16.5%)	31 (8.7%)	
Some College	126 (21.2%)	50 (21.1%)	76 (21.3%)	

College+	375 (63.1%)	132 (55.7%)	243 (68.1%)	
Race, n (%)				0.256†
White	543 (91.4%)	222 (93.7%)	321 (89.9%)	
Black	33 (5.6%)	8 (3.4%)	25 (7.0%)	
Asian	12 (2.0%)	4 (1.7%)	8 (2.2%)	
Other/Multiple	6 (1.0%)	3 (1.3%)	3 (0.8%)	
Genetics				
APOE e4 alleles, n (%)				<0.001† [0.45, 0.67]
0	335 (56%)	78 (33%)	257 (72%)	
1	202 (34%)	112 (47%)	90 (25%)	
2	57 (10%)	47 (20%)	10 (3%)	
Clinical Scores				
MMSE, mean (SD)	27.0 (3.2)	23.0 (2.0)	29.0 (1.1)	<0.001‡ [5.5, 6.1]
Median [IQR]	28 [24-30]	23 [22-25]	29 [29-30]	
CDR-SB, mean (SD)	1.7 (2.3)	4.3 (1.6)	0.0 (0.0)	<0.001‡ [4.1, 4.5]
Median [IQR]	0 [0-4]	4 [3.5-5]	0 [0-0]	

†Pearson's chi-squared test; ‡Welch's two-sample t-test. **Abbreviations:** AD, Alzheimer disease; *APOE*, apolipoprotein E; CDR-SB, Clinical Dementia Rating Scale-Sum of Boxes; CN, cognitively normal; IQR, interquartile range; MMSE, Mini-Mental State Examination; SD, standard deviation. Categorical variables (e.g., **sex**, *APOE* ε4 allele status) were compared using *Pearson χ^2 tests*. Continuous variables (e.g., **age**, **MMSE**, and **CDR-SB** scores) were compared using *Welch t tests*. Data are presented as **No. (%)**, **mean (SD)**, **median [interquartile range]**, or **range (min-max;** Q1-Q3), as appropriate. *Confidence intervals (CIs)* for between-group differences are reported for proportions and means; CIs for proportions were derived using the *Wald method*, and CIs for means were based on the *t-distribution*. Education level categorized by years: <12 = "< High School", 12 = "High School", 13–15 = "Some College", ≥16 = "College+"

Algorithm comparison and model optimization

Evaluation of the five machine learning algorithms on the independent test set revealed that the LASSO and PLS models generally outperformed the other methods in terms of consistency and overall discriminative power (Fig 2A, Table S1). Permutation-based null distributions confirmed that the observed classification accuracy was significantly better than chance (p< 0.001) (Fig 2B). PLS model exhibited a pronounced sensitivity-specificity trade-off, achieving an exceptionally high sensitivity (0.99) but at the cost of lower specificity (0.63). This indicates that while PLS is effective at identifying almost all AD cases, it produces a high number of false positives in cognitively normal individuals. In contrast, the LASSO model provided a

more balanced and harmonized performance across all metrics (Table S2).

Fig 2. Model performance and metabolite importance in predictive analysis.

(A) ROC curves comparing the performance of machine learning models (LASSO, PLS,

XGBoost, Random Forest, Naive Bayes) on the test set, with LASSO and PLS showing the

highest AUC (0.89). (B) Permutation test with shuffling of training labels only, evaluated on an

untouched test set, results confirming the robustness of the LASSO model (actual AUC =

0.89). (C) Bar plot of the top 25 metabolites ranked by importance scores from LASSO,

highlighting key biomarkers such as CDCA and t4-OH-Pro. (D) Relationship between the

number of metabolites and model performance (AUC), with the optimal subset (151

metabolites) achieving an AUC of 0.9.

Analysis of the relationship between the number of metabolites and model performance

indicated a clear plateauing effect (Fig 2D). While initial performance increased rapidly as the

first 50 metabolites were added, the gain in AUC became marginal beyond 150 features, which

argued against the need for exhaustive metabolite panels, instead pointing to a finite set of

mechanistically interlinked analytes. The "Optimal Model" was therefore defined as a LASSO-

based classifier utilizing 151 metabolites. This optimized 151-metabolite panel distinguished

AD from CN with an AUC of 0.90 (Fig 2D).

Models trained on combined metabolite data and *APOE* genotypes yielded higher AUCs

compared to using metabolomics data or *APOE* alone (Fig 3A). This indicates that metabolic

profiles provide substantial predictive information beyond genetic risk. Of translational

relevance, the incremental predictive value of *APOE* status when combined with metabolomics

supported a precision medicine approach where genomic context enhances metabolic risk

stratification. The combined model correctly identified 88% of CN and 91% of AD cases, a

marked improvement over *APOE*-only predictions (75% CN, 55% AD) (Fig 3B).

Fig 3. Performance comparison machine learning (ML) models with and without _APOE_

in AD Classification.

(A) ROC curves comparing LASSO models trained with metabolites only (AUC = 0.90),

metabolites + _APOE_ (AUC = 0.91), and _APOE_ alone (AUC = 0.75) for binary classification of

AD vs. cognitively normal (CN) participants. The optimal model (m=151 features)

demonstrates improved performance when _APOE_ is combined with metabolomic data (B)

Confusion matrices and (C) performance metrics (sensitivity, specificity, precision, accuracy)

for each model variant. The LASSO model with _APOE_ achieves the highest balanced accuracy.

The LASSO model trained on combined features achieved the best results: mean

cross-validated AUC of 0.90 (95% CI: 0.88-0.93 with 2000 stratified bootstrap replicates) on

top 151 metabolites (Table S1). The final test-set reached AUC of 0.91 (95% CI, 0.87-0.96)

with accuracy, recall, precision, and specificity consistently in the high range (Table S2; Fig

3B).

Key metabolites and biological signature

The top predictor was the primary bile acid chenodeoxycholic acid (CDCA), followed by 4-

hydroxyproline (t4-OH-Pro) and tetradecane dioic acid (DiCA(14:0)). Collectively, these three

metabolites accounted for >60% of the total feature importance in the model (Fig 2C). While

APOE ε4 status alone showed moderate predictive power (AUC = 0.75), its integration with

metabolomics significantly improved model performance (ΔAUC = +0.16 vs. _APOE_-only;

p<0.001).

The 151-metabolite panel encompassed 22 distinct biochemical classes (Fig S2, Table S3).

Lipid species were most represented, with triglycerides, diglycerides, and phosphatidylcholines

as dominant subclasses. Several amino acid-related pathways were enriched, including

derivatives such as t4-OH-Pro (involved in collagen turnover) and arginine-related metabolites

(implicated in nitric oxide signaling), both relevant to vascular contributions to dementia.

Multiple sphingolipid subclasses (e.g., ceramides) were identified, aligning with evidence of

sphingolipid dysregulation in AD. The high ranking of bile acids underscores the involvement

of interconnected pathways spanning energy metabolism, inflammation, and gut-liver-brain

axis signaling in AD. Major functional clusters are summarized in Table 2.

Table 2. Major functional clusters of identified metabolites

Functional clusters	Representative Metabolites	Pathophysiological Context
Bile acid signaling	• Chenodeoxycholic acid (CDCA) • Deoxycholic acid (DCA) • Trimethylcholic acid (TMCA), • Glycolithocholic acid (GLCA)	Critical components of the gut-liver-brain axis, influencing cholesterol metabolism and systemic inflammation (16)
Lipid membrane and signaling	• Diacylglycerols (e.g., DG(18:2_18:3)) • Ether-linked phosphatidylcholines (e.g., PC ae C42:1, PC ae C36:5)	Diacylglycerols are augmented in AD brain and plasma and play roles in membrane structure and protein-kinase-C signaling (17) and Ether lipids are essential for neural membrane integrity, lipid-raft organization, and antioxidant defense (18)
Mitochondrial and energy markers	• Multiple acylcarnitines (C3, C5-M-DC, C7-DC, C0, C10)	Plasma acylcarnitines reflect altered mitochondrial fatty-acid β-oxidation; medium-chain acylcarnitines are significantly lower in AD patients (19)
Amino Acid and Collagen Metabolism	• 4-Hydroxyproline (t4-OH-Pro) • Arginine derivatives	Hydroxyproline, a collagen-breakdown product, is correlated with age and AD (20). The L-arginine/NO pathway is altered in AD, affecting vascular integrity and nitric-oxide signaling (21).
Sphingolipid Metabolism	• Ceramides • Hexosylceramides	Sphingolipid metabolism is disturbed in AD; ceramide levels are elevated in AD brains and contribute to membrane structure, apoptosis, and myelination(22)

4. Discussion

Clinical-metabolomic integration and multi-omics synergy

The core insight of this study is that serum metabolomics and *APOE* ε4 status provide

synergistic information that enhances AD detection far beyond the capacity of either modality

alone. In the independent test set, the integration of *APOE* ε4 into the metabolic model resulted

in an absolute improvement in AUC of 0.16 compared to using *APOE* alone (0.91 vs 0.75;

Table S2). This synergistic effect supports a precision medicine framework where genomic risk

(the "predisposition") is combined with the metabolic state (the "manifestation") to refine risk

stratification (23–26).

A second-order inference from this synergy is that *APOE* ε4 does not act on AD risk through a

single pathway but rather creates a unique metabolic "soil" that is more receptive to

pathological processes. The *APOE* ε4 allele is known to impair lipid transport and exacerbate

neuroinflammation; the current finding that a lipid-dominated metabolic signature (Fig S2)

provides such a strong additive signal suggests that our model is capturing the specific

metabolic consequences of being an ε4 carrier. This aligns with recent multi-omics frameworks

that position AD as a "network disorder" where genomic susceptibility and downstream

metabolic dysfunction (such as lipid peroxidation and mitochondrial stress) co-accelerate

neurodegeneration (27).

Systematic breakdown of lipidomic and membrane pathology

The dominance of lipid species in the prioritized 151-metabolite panel ($n=62$ total lipid

species including TGs, DGs, and PCs) provides robust evidence for systemic membrane

pathology in AD (28). Phosphatidylcholines are the primary building blocks of neuronal and

mitochondrial membranes.8 The presence of numerous ether-linked species (designated with

the "ae" prefix in the Biocrates panel, such as PC ae C42:1 and PC ae C36:5) is particularly

significant.1 Ether lipids, which include plasmalogens, are highly enriched in lipid rafts and act

as critical antioxidants that protect cellular components from oxidative stress. Similar lipid

dominance also aligned with post-mortem studies of AD brain tissue but contrasted with

association of *APOE* standalone with amyloid pathology, shows that the model captured

distinct, potentially co-occurring disease mechanisms (29,30).

A third-order insight here is that the serum metabolic changes we detected likely reflect a

global breakdown in lipid raft homeostasis. Lipid rafts are specialized membrane

microdomains where the processing of amyloid precursor protein (APP) occurs; disruptions in

these domains have been shown to shift APP processing toward the amyloidogenic pathway,

increasing the production of Aβ42. The fact that these lipid signatures are detectable in serum

indicates that AD pathology involves a systemic failure of membrane integrity that extends

beyond the central nervous system, offering a rationale for using blood-based metabolomics as

a scalable proxy for brain health.

The gut-liver-brain axis and peripheral cholesterol homeostasis

The ranking of chenodeoxycholic acid (CDCA) as the most discriminative feature in the panel

highlights the importance of the gut-liver-brain axis in AD pathophysiology. Bile acids are

synthesized from cholesterol in the liver and are further metabolized by the gut microbiome

into secondary bile acids like deoxycholic acid (DCA), which also ranked among the top

features ($n=9$).

This connection between bile acids and AD suggests several deep-seated biological trends:

• **Impaired cholesterol clearance:** Altered bile acid profiles in the serum indicate that

the peripheral mechanisms for cholesterol disposal are compromised in individuals with

AD, potentially leading to the systemic lipid dysregulation captured by the rest of the

panel (9).

- **Microbiome involvement**: The inclusion of secondary bile acids and microbial metabolites like indole-3-acetic acid (3-IAA) and hipuric acid points to a disruption in the gut microbiome. Growing evidence suggests that gut-derived metabolites can cross the blood-brain barrier and influence neuroinflammation through the farnesoid X receptor (FXR) and the TGR5 receptor, both of which are expressed in the brain and are sensitive to bile acid signaling.

- **Neuroprotective failures:** Bile acids like CDCA are not just metabolic waste products; they are potent signaling molecules that regulate mitochondrial function and energy homeostasis (16). Their disruption at baseline in the ADNI cohort indicates that these protective signaling pathways are already failing in the early stages of the disease.

Vascular contributions and extracellular matrix turnover

The identification of 4-hydroxyproline (t4-OH-Pro) as the second most important feature provides a crucial insight into the non-amyloid components of AD. 4-hydroxyproline is a modified amino acid almost exclusively found in collagen; its circulating levels are a direct reflection of collagen turnover and extracellular matrix remodeling.

In the context of AD, this finding likely signals a significant vascular contribution to the disease phenotype. Small vessel disease and the breakdown of the blood-brain barrier (BBB) are nearly universal comorbidities in AD (9). The BBB relies on a robust vascular basement membrane, which is primarily composed of type IV collagen. Elevated or altered levels of t4-OH-Pro in serum may therefore represent the systemic "leakiness" of the vasculature or the degradation of the basement membrane that facilitates the infiltration of neurotoxic peripheral factors into the brain. This captures a facet of "biological aging" and vascular health that is

312 distinct from amyloid-tau-neurodegeneration (ATN) biomarkers, explaining why our model

313 provides complementary information to proteomic tests.

Mitochondrial exhaustion and acylcarnitine profiles

The presence of 12 distinct acylcarnitines in the 151-metabolite panel (including C3, C5-M-

DC, and C10) points to mitochondrial dysfunction as a core component of the AD metabolic

signature. Acylcarnitines are essential intermediates in the transport of fatty acids into the

mitochondria for β-oxidation. Disruptions in these levels suggest a shift in energy utilization

and mitochondrial "exhaustion," where the brain and peripheral tissues may be failing to

efficiently utilize lipids as an alternative fuel source to glucose.

Specifically, the short-chain acylcarnitine C3 is a byproduct of the catabolism of branched-

chain amino acids (BCAAs). Altered BCAA metabolism has been repeatedly identified in large

cohorts like the UK Biobank as a predictor of incident AD, suggesting that systemic failures in

amino acid metabolism and mitochondrial energy production are early events that occur

alongside, or even before, clinical symptoms.

Clinical potential for rule-out screening and population health

The performance of our combined metabolomic-genomic model (AUC = 0.91) is highly

competitive with current clinical gold standards, yet it offers significant advantages in terms of

scalability and cost. While PET imaging and CSF assays remain the diagnostic definitive tests

(31), they are ill-suited for large-scale population screening due to their invasive nature and the

requirement for specialized infrastructure.

The high negative predictive value (NPV) of 0.94 is particularly transformative for primary

care settings. In a triage scenario, the primary utility of a blood-based biomarker is to "rule out"

AD in patients presenting with mild cognitive complaints, thereby avoiding the high cost and

potential risks of unnecessary invasive referrals (31,32). A screening tool that can correctly

identify 94% of true negatives could drastically optimize healthcare resource allocation while

ensuring that high-risk individuals are prioritized for more expensive confirmatory tests.

Furthermore, our model aligns with the July 2025 Palmqvist guidelines (3), which endorse

blood-based biomarkers with at least 90% sensitivity and 75% specificity for clinical use. By

meeting and exceeding these thresholds (0.92 sensitivity, 0.84 specificity), the 151-metabolite

panel integrated with *APOE* represents a regulatory-grade candidate for baseline disease

stratification.

Comparisons with previous large-scale studies

Compared to earlier metabolomics studies, which were often restricted to small "pilot" samples

of ~100 individuals (25), our analysis of 594 participants provides a higher level of statistical

power and robustness. The consistency of our AUC (0.91) with findings from the UK Biobank

(AUC 0.86–0.87 for incident AD) (33–35) confirms that metabolic signatures provide a stable

and reproducible signal across different cohorts and platforms.

Our study also reinforces the specific metabolite classes identified in recent multi-omics ADNI

investigations (33–35), particularly the involvement of ether lipids and acylcarnitines.

However, by providing absolute quantification via the Biocrates platform, our panel offers a

level of standardization and translational relevance that untargeted "discovery-based"

metabolomics often lacks. This standardized approach is critical for the development of

clinical-grade diagnostic assays that must perform reliably across different laboratories.

Technical robustness and algorithmic considerations

The superiority of LASSO and PLS algorithms over more complex ensemble methods like

Random Forest or XGBoost is a noteworthy technical finding. Metabolomic data is

characterized by "wide" datasets (thousands of features, hundreds of samples) and high

multicollinearity. The regularized linear approach of LASSO is inherently better suited for this

structure because it prevents overfitting by shrinking redundant coefficients to zero, a

capability that ensemble methods, which are prone to over-fitting high-dimensional noise, may

lack in smaller cohorts.

The plateau in performance at 151 metabolites is another key insight, arguing against the need

for exhaustive panels of 600+ metabolites. This indicates that there is a finite, biologically

interlinked set of analytes that capture the core metabolic variance of AD. From a clinical

development perspective, a focused 151-metabolite panel is significantly easier to validate,

manufacture, and clear through regulatory agencies than a larger, less interpretable signature.

Comparative context for identified blood-based metabolite classes

The broad biochemical spectrum captured by our top-ranked metabolites; spanning lipids, bile

acids, and amino acid derivatives; supports prior findings that AD involves complex,

multisystem metabolic disturbances. Previous metabolomics studies have similarly reported

elevated acylcarnitines and disrupted phospholipid profiles in AD and mild cognitive

impairment (MCI) cohorts, though often using narrower panels or untargeted platforms with

limited clinical utility (36). In contrast, our panel provides absolute quantification and

regulatory-grade standardization, enhancing translational relevance.

Notably, while CSF biomarkers and PET imaging remain clinical gold standards, they are

invasive or costly. In comparison, our blood-based metabolite panel integrated with *APOE*

genotype achieved classification performance (AUC=0.91) that is competitive with, and in

some contexts exceeds, reported accuracies from imaging-based diagnostics (37). This

supports the growing rationale for metabolomics-driven precision medicine, where metabolic

signatures provide complementary, accessible, and biologically informative tools for early AD

risk stratification.

Evaluation of limitations and generalizability

While the current results are robust, several limitations must be acknowledged. First, the ADNI

cohort is predominantly white and North American, which may limit the generalizability of the

metabolic signature to more diverse populations where dietary habits, environmental

exposures, and genetic backgrounds (beyond *APOE*) are different. Second-order implications

of this bias suggest that the specific rankings of metabolites like bile acids, which are heavily

influenced by diet and the microbiome, might shift in international cohorts (38). Validation in

more representative datasets, such as ARIC or UK Biobank, is essential (39).

In addition, the cross-sectional baseline design of this study means that the signature represents

a "snapshot" of established disease rather than a predictor of conversion. Longitudinal studies

are required to determine if these 151 metabolites can identify "converters" who are

cognitively normal at baseline but will progress to MCI or AD within 2–5 years. Finally, while

PQN normalization and rigid QC protocols were used, potential batch effects remain an

inherent concern in large-scale multicenter studies like ADNI.

Future directions: Network-based machine learning and precision prevention

Looking forward, the integration of metabolomics into the AD clinical workflow could be

further enhanced by "explainable" machine learning frameworks. One such promising

approach is explainable graph-theoretical machine learning (XGML) (40,41). Rather than

treating metabolites as independent features, XGML models them as nodes in a metabolic

network. By identifying the "edges" or biochemical connections that are most disrupted in AD,

we can move from simple diagnostic classification to a deeper understanding of the causal

neural-metabolic mechanisms.

Moreover, the synergy between *APOE* ε4 and metabolic signatures opens the door for

precision prevention strategies. If ε4 carriers exhibit a specific "lipidomic failure" pattern,

targeted nutritional or pharmacological interventions aimed at stabilizing lipid rafts or

modulating the gut-liver-brain axis (e.g., through bile acid sequestrants or specific probiotics)

could potentially delay the onset of symptoms. This move toward "interventional

metabolomics" represents the next frontier in AD research, where biomarkers are used not just

for detection but as dynamic guides for therapy (42).

413   5. Conclusion

This study provides a comprehensive and robust validation of a serum-based metabolomic

panel for the accurate baseline detection of Alzheimer's disease. By integrating absolute

quantification of 151 prioritized metabolites with *APOE* ε4 genotype status, we have

developed a signature that achieves an AUC of 0.91, meeting the rigorous performance

standards for clinical triage in specialized memory care settings. The predictive model is

characterized by a high negative predictive value (0.94), making it an ideal candidate for rule-

out screening in primary care to reduce the burden of unnecessary invasive diagnostics.

The biological insights derived from this study underscore AD as a systemic metabolic

disorder, where failures in lipid membrane integrity, gut-liver-brain signaling (bile acids),

vascular basement membrane turnover (4-hydroxyproline), and mitochondrial energy

production (acylcarnitines) converge to drive pathology. The significant synergy between

genetic risk and metabolic manifestation validates the multi-omics approach to

neurodegenerative disease stratification. While future validation in diverse, longitudinal

cohorts is required to confirm generalizability, these findings represent a critical step toward

the goal of providing accessible, accurate, and biologically informative tools for the global

management of Alzheimer's disease.

430 6. References

1. Commissioner O of the. FDA. FDA; 2025 [cited 2025 Aug 12]. FDA Clears First Blood
Test Used in Diagnosing Alzheimer's Disease. Available from: https://www.fda.gov/news-
events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-
disease

2. Hu S, Yu H, Gao J. The pTau217/Aβ1-42 plasma ratio: The first FDA-cleared blood
biomarker test for diagnosis of Alzheimer's disease. Drug Discov Ther. 2025 Jul
4;19(3):208–9.

3. Palmqvist S, Whitson HE, Allen LA, Suarez-Calvet M, Galasko D, Karikari TK, et al.
Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers
in the diagnostic workup of suspected Alzheimer's disease within specialized care settings.
Alzheimer's & Dementia [Internet]. 2025 [cited 2025 Aug 12];21(7):e70535. Available
from: https://onlinelibrary.wiley.com/doi/abs/10.1002/alz.70535

4. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association
Workgroup - Jack - 2024 - Alzheimer's & Dementia - Wiley Online Library [Internet].
[cited 2025 Aug 12]. Available from: https://alz-
journals.onlinelibrary.wiley.com/doi/10.1002/alz.13859

5. Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, et al. Alzheimer
Disease as a Clinical-Biological Construct—An International Working Group
Recommendation. JAMA Neurol [Internet]. 2024 Dec 1 [cited 2025 Aug 12];81(12):1304–
11. Available from: https://doi.org/10.1001/jamaneurol.2024.3770

6. Smirnov DS, Ashton NJ, Blennow K, Zetterberg H, Simrén J, Lantero-Rodriguez J, et al.
Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive
change. Acta Neuropathol [Internet]. 2022 Apr 1 [cited 2024 Jul 4];143(4):487–503.
Available from: https://doi.org/10.1007/s00401-022-02408-5

7. Casanova R, Varma S, Simpson B, Kim M, An Y, Saldana S, et al. Blood metabolite
markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older
individuals. Alzheimer's & Dementia [Internet]. 2016 Jul [cited 2025 Jul
27];12(7):815–22. Available from: https://alz-
journals.onlinelibrary.wiley.com/doi/10.1016/j.jalz.2015.12.008

8. Oka T, Matsuzawa Y, Tsuneyoshi M, Nakamura Y, Aoshima K, Tsugawa H. Multiomics
analysis to explore blood metabolite biomarkers in an Alzheimer's Disease Neuroimaging
Initiative cohort. Sci Rep [Internet]. 2024 Apr 2 [cited 2024 Nov 4];14(1):6797. Available
from: https://www.nature.com/articles/s41598-024-56837-1

9. Jack Jr. CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria
for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.

Alzheimer's & Dementia [Internet]. 2024 [cited 2025 Aug 19];20(8):5143–69. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/alz.13859

10. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement [Internet]. 2018 Apr [cited 2025 Aug 19];14(4):535–62. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958625/

11. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach. Biometrics [Internet]. 1988 [cited 2025 Jul 30];44(3):837–45. Available from: https://www.jstor.org/stable/2531595

12. Bandos AI, Rockette HE, Gur D. A permutation test sensitive to differences in areas for comparing ROC curves from a paired design. Statist Med [Internet]. 2005 Sep 30 [cited 2025 Jul 30];24(18):2873–93. Available from: https://onlinelibrary.wiley.com/doi/10.1002/sim.2149

13. Efron B, Tibshirani RJ. An Introduction to the Bootstrap [Internet]. 0 ed. Chapman and Hall/CRC; 1994 [cited 2025 Jul 30]. Available from: https://www.taylorfrancis.com/books/9781000064988

14. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics [Internet]. 2011 Dec [cited 2025 Jul 30];12(1):77. Available from: https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-12-77

15. Kuhn M. Building Predictive Models in *R* Using the **caret** Package. J Stat Soft [Internet]. 2008 [cited 2025 Jul 30];28(5). Available from: http://www.jstatsoft.org/v28/i05/

16. MahmoudianDehkordi S, Arnold M, Nho K, Ahmad S, Jia W, Xie G, et al. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome. Alzheimer's & Dementia [Internet]. 2019 Jan [cited 2026 Jan 16];15(1):76–92. Available from: https://alz-journals.onlinelibrary.wiley.com/doi/10.1016/j.jalz.2018.07.217

17. Wood PL, Medicherla S, Sheikh N, Terry B, Phillipps A, Kaye JA, et al. Targeted Lipidomics of Fontal Cortex and Plasma Diacylglycerols (DAG) in Mild Cognitive Impairment and Alzheimer's Disease: Validation of DAG Accumulation Early in the Pathophysiology of Alzheimer's Disease. JAD [Internet]. 2015 Sep 9 [cited 2026 Jan 16];48(2):537–46. Available from: https://journals.sagepub.com/doi/full/10.3233/JAD-150336

18. Jové M, Mota-Martorell N, Obis È, Sol J, Martín-Garí M, Ferrer I, et al. Ether Lipid-Mediated Antioxidant Defense in Alzheimer's Disease. Antioxidants [Internet]. 2023 Jan 28 [cited 2026 Jan 16];12(2):293. Available from: https://www.mdpi.com/2076-3921/12/2/293

19. Ciavardelli D, Piras F, Consalvo A, Rossi C, Zucchelli M, Di Ilio C, et al. Medium-chain plasma acylcarnitines, ketone levels, cognition, and gray matter volumes in healthy elderly, mildly cognitively impaired, or Alzheimer's disease subjects. Neurobiology of Aging

[Internet]. 2016 Jul [cited 2026 Jan 16];43:1–12. Available from:
https://linkinghub.elsevier.com/retrieve/pii/S0197458016002037

20. Ma X, Wang XM, Tang GZ, Wang Y, Liu X, Wang SD, et al. Alterations of amino acids in
older adults with Alzheimer's Disease and Vascular Dementia. Amino Acids [Internet].
2025 Jan 18 [cited 2026 Jan 16];57(1):10. Available from:
https://link.springer.com/10.1007/s00726-024-03442-1

21. Fleszar MG, Wiśniewski J, Zboch M, Diakowska D, Gamian A, Krzystek-Korpacka M.
Targeted metabolomic analysis of nitric oxide/L-arginine pathway metabolites in dementia:
association with pathology, severity, and structural brain changes. Sci Rep [Internet]. 2019
Sep 24 [cited 2026 Jan 16];9(1):13764. Available from:
https://www.nature.com/articles/s41598-019-50205-0

22. Uranbileg B, Isago H, Sakai E, Kubota M, Saito Y, Kurano M. Alzheimer's disease
manifests abnormal sphingolipid metabolism. Front Aging Neurosci [Internet]. 2024 May
7 [cited 2026 Jan 16];16:1368839. Available from:
https://www.frontiersin.org/articles/10.3389/fnagi.2024.1368839/full

23. Cao Y, Meng L, Wang Y, Zhao S, Zheng Y, Ran R, et al. Large-scale prospective serum
metabolomic profiling reveals candidate predictive biomarkers for suspected preeclampsia
patients. Sci Rep [Internet]. 2025 Feb 9 [cited 2025 Jul 28];15(1):4807. Available from:
https://www.nature.com/articles/s41598-025-87905-9

24. Miranda AM, Ashok A, Chan RB, Zhou B, Xu Y, McIntire LB, et al. Effects of APOE4
allelic dosage on lipidomic signatures in the entorhinal cortex of aged mice. Transl
Psychiatry [Internet]. 2022 Mar 29 [cited 2025 Jul 28];12(1):129. Available from:
https://www.nature.com/articles/s41398-022-01881-6

25. Mukesha D, Sarter M, Dubray M, Durand F, Boutillier S, Pham-Van LD, et al. Targeted
serum metabolomic profiling and machine learning approach in Alzheimer's disease using
the Alzheimer's disease diagnostics clinical study (ADDIA) cohort. J Alzheimers Dis
[Internet]. 2025 Sep 26 [cited 2025 Dec 5];108(2):824–33. Available from:
https://pmc.ncbi.nlm.nih.gov/articles/PMC12614907/

26. Mukesha D, Sarter M, Dubray M, Durand F, Kul S, Pham☐Van L, et al. Metabolomic
Signatures and Machine Learning Models for Distinguishing Alzheimer's Disease and
Dementia with Lewy Bodies. Alzheimer's & Dementia [Internet]. 2025 Dec [cited
2025 Dec 27];21(S9):e110610. Available from: https://alz-
journals.onlinelibrary.wiley.com/doi/10.1002/alz70863_110610

27. Guo Y, Zou H, Alam MS, Luo S. Integrative Multi-Omics and Multivariate Longitudinal
Data Analysis for Dynamic Risk Estimation in Alzheimer's Disease. Statistics in Medicine
[Internet]. 2025 [cited 2025 Jul 28];44(10–12):e70105. Available from:
https://onlinelibrary.wiley.com/doi/abs/10.1002/sim.70105

28. Toledo JB, Arnold M, Kastenmüuller G, Chang R, Baillie RA, Han X, et al. Metabolic
network failures in Alzheimer's disease: A biochemical road map. Alzheimers Dement
[Internet]. 2017 Sep [cited 2025 Jul 28];13(9):965–84. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866045/

29. Odenkirk MT, Zheng X, Kyle JE, Stratton KG, Nicora CD, Bloodsworth KJ, et al.
Deciphering ApoE Genotype-Driven Proteomic and Lipidomic Alterations in Alzheimer's
Disease Across Distinct Brain Regions. J Proteome Res [Internet]. 2024 Aug 2 [cited 2025
Jul   28];23(8):2970–85.   Available   from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11255128/

30. Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer's Disease: Advances in
Genetics, Pathophysiology, and Therapeutic Approaches. Lancet Neurol [Internet]. 2021
Jan   [cited   2025   Jul   28];20(1):68–80.   Available   from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096522/

31. Recommendations for sample selection, collection and preparation for NMR-based
metabolomics studies of blood | Metabolomics [Internet]. [cited 2025 Jul 28]. Available
from: https://link.springer.com/article/10.1007/s11306-025-02259-7

32. Hajian-Tilaki K. Receiver Operating Characteristic (ROC) Curve Analysis for Medical
Diagnostic Test Evaluation. Caspian J Intern Med [Internet]. 2013 [cited 2025 Jul
28];4(2):627–35.   Available   from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755824/

33. Gianattasio KZ, Bennett EE, Wei J, Mehrotra ML, Mosley T, Gottesman RF, et al.
Generalizability of findings from a clinical sample to a community-based sample: A
comparison of ADNI and ARIC. Alzheimers Dement [Internet]. 2021 Aug [cited 2025 Jul
28];17(8):1265–76.   Available   from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359773/

34. Capó M, Vitali S, Athanasiou G, Cusimano N, García D, Cruickshank G, et al. UK
Biobank MRI data can power the development of generalizable brain clocks: A study of
standard ML/DL methodologies and performance analysis on external databases.
NeuroImage [Internet]. 2025 Mar 1 [cited 2025 Jul 28];308:121064. Available from:
https://www.sciencedirect.com/science/article/pii/S1053811925000667

35. Zhang X, Hu W, Wang Y, Wang W, Liao H, Zhang X, et al. Plasma metabolomic profiles
of dementia: a prospective study of 110,655 participants in the UK Biobank. BMC Med
[Internet].   2022   Aug   15   [cited   2025   Jul   28];20:252.   Available   from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377110/

36. Shao Y, Ouyang Y, Li T, Liu X, Xu X, Li S, et al. Alteration of Metabolic Profile and
Potential Biomarkers in the Plasma of Alzheimer's Disease. Aging and disease [Internet].
2020   [cited   2025   Sep   4];11(6):1459.   Available   from:
http://www.aginganddisease.org/EN/10.14336/AD.2020.0217

37. Perron J, Scramstad C, Ko JH. Brain metabolic imaging-based model identifies cognitive
stability in prodromal Alzheimer's disease. Sci Rep [Internet]. 2025 May 17 [cited 2025
Sep 4];15(1):17187. Available from: https://www.nature.com/articles/s41598-025-02039-2

38. Shaaban CE, Tudorascu DL, Glymour MM, Cohen AD, Thurston RC, Snyder HM, et al. A
guide for researchers seeking training in retrospective data harmonization for population
neuroscience studies of Alzheimer's disease and related dementias. Front Neuroimaging
[Internet].   2022   Sep   26   [cited   2026   Jan   16];1:978350.   Available   from:
https://www.frontiersin.org/articles/10.3389/fnimg.2022.978350/full

39. Stapp EK, Mayeda ER, Stuart EA, Gottesman RF, Zimmerman SC, Wong DF, et al.
Estimating preclinical amyloid positivity: A case study transporting ADNI to ARIC.
Alzheimer's & Dementia: Translational Research & Clinical Interventions [Internet]. 2025
[cited   2026   Jan   16];11(4):e70158.   Available   from:
https://onlinelibrary.wiley.com/doi/abs/10.1002/trc2.70158

40. Alatrany AS, Khan W, Hussain A, Kolivand H, Al-Jumeily D. An explainable machine
learning approach for Alzheimer's disease classification. Sci Rep [Internet]. 2024 Feb 1
[cited 2025 Mar 11];14(1):2637. Available from: https://www.nature.com/articles/s41598-
024-51985-w

41. Liu Y, Huse J, Kannan K. Expression graph network framework for biomarker discovery.
Briefings in Bioinformatics [Internet]. 2025 Aug 31 [cited 2026 Jan 16];26(5):bbaf559.
Available from: https://academic.oup.com/bib/article/doi/10.1093/bib/bbaf559/8303424

42. Ki MR, Kim DH, Abdelhamid MAA, Pack SP. Cancer and Aging Biomarkers:
Classification, Early Detection Technologies and Emerging Research Trends. Biosensors
[Internet].   2025   Nov   4   [cited   2026   Jan   16];15(11):737.   Available   from:
https://www.mdpi.com/2079-6374/15/11/737

7. Acknowledgements

The realization of this project was supported and funded by **CombiDiag**, HORIZON – MSCA Doctoral Networks 2021 program under grant agreement (GA): **101071485**. Data collection and sharing for this project were funded by the **Alzheimer's Disease Neuroimaging Initiative (ADNI)** (National Institutes of Health Grant **U01 AG024904**; Department of Defense award **W81XWH-12-2-0012**).

ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following organizations: AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics.

The Canadian Institutes of Health Research provides funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

8. Fundings, Conflicts of Interest, and Ethics

Funding

This research was supported by **CombiDiag** (HORIZON – MSCA Doctoral Networks 2021,

GA: 101071485). Data collection and sharing were supported by the Alzheimer's Disease

Neuroimaging Initiative (ADNI).

The funders had **no role** in the design and conduct of the study; collection, management,

analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or

the decision to submit the manuscript for publication.

Conflicts of interest

The authors declare no conflicts of interest related to this study.

Ethics Approval and Consent

There were no experiments involving animal subjects in this study. Procedures involving

human participants were conducted in accordance with the ethical standards of the institutional

review boards of the participating ADNI sites and in accordance with the Helsinki Declaration

of 1975.

Written informed consent was obtained from all participants by the ADNI study investigators.

No identifiable individual data were used in this manuscript.

Data Availability

The data supporting the findings of this study are available in the public domain from the

Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Access is available to

qualified researchers upon application at https://adni.loni.usc.edu/.

Trial registration

Data used in this study were obtained from the Alzheimer's Disease Neuroimaging Initiative

(ADNI) database (ClinicalTrials.gov Identifiers: **NCT00106899**, **NCT01078636**,

NCT01231971, **NCT02854033**). No new raw data were generated for this study; all analyses

were conducted on existing ADNI data.

A) ROC Curves on Test Set
Comparison of Machine Learning Models on Held-Out Data

151 metabolites + APOE (AUC = 0.91 [0.87–0.96])
151 metabolites (AUC = 0.90 [0.85–0.94])
APOE alone (AUC = 0.75 [0.68–0.81])

Binary classification: AD vs CN

B) Confusion Matrices for Optimal Models with/without APOE

Optimal model (151 metabolites)

C) Performance of Metabolites-APOE-based Models

Model	Accuracy	AUC	F1 Score	Kappa	Sensitivity	Specificity
151 metabolites + APOE	0.87	0.91	0.85	0.74	0.92	0.84
151 metabolites	0.82	0.9	0.78	0.62	0.81	0.82
APOE alone	0.72	0.75	0.69	0.44	0.76	0.69